

Adam Cuker

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4117254/publications.pdf>

Version: 2024-02-01

193
papers

10,847
citations

50276

46
h-index

33894

99
g-index

196
all docs

196
docs citations

196
times ranked

10869
citing authors

#	ARTICLE	IF	CITATIONS
1	Cost-effectiveness of second-line therapies in adults with chronic immune thrombocytopenia. <i>American Journal of Hematology</i> , 2023, 98, 122-130.	4.1	7
2	SARS-CoV-2 vaccination and ITP in patients with de novo or preexisting ITP. <i>Blood</i> , 2022, 139, 1564-1574.	1.4	55
3	Optimal Medical Therapy Following Deep Venous Interventions: Proceedings from the Society of Interventional Radiology Foundation Research Consensus Panel. <i>Journal of Vascular and Interventional Radiology</i> , 2022, 33, 78-85.	0.5	6
4	American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: July 2021 update on postdischarge thromboprophylaxis. <i>Blood Advances</i> , 2022, 6, 664-671.	5.2	53
5	Risk for Recurrent Venous Thromboembolism and Bleeding With Apixaban Compared With Rivaroxaban: An Analysis of Real-World Data. <i>Annals of Internal Medicine</i> , 2022, 175, 20-28.	3.9	31
6	Postoperative bleeding complications in patients with hemophilia undergoing major orthopedic surgery: A prospective multicenter observational study. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 857-865.	3.8	14
7	Apixaban has superior effectiveness and safety compared to rivaroxaban in patients with commercial healthcare coverage: A population-based analysis in response to CVS 2022 formulary changes. <i>American Journal of Hematology</i> , 2022, 97, .	4.1	3
8	Adults with immune thrombocytopenia who switched to avatrombopag following prior treatment with eltrombopag or romiplostim: A multicentre US study. <i>British Journal of Haematology</i> , 2022, 197, 359-366.	2.5	31
9	Cerebral Infarction due to Severe ADAMTS-13 Deficiency with Normal Hematological Parameters: A Cause of Cryptogenic Stroke. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2022, 31, 106431.	1.6	2
10	American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: January 2022 update on the use of therapeutic-intensity anticoagulation in acutely ill patients. <i>Blood Advances</i> , 2022, 6, 4915-4923.	5.2	42
11	Prophylactic fresh frozen plasma versus prothrombin complex concentrate for preprocedural management of the coagulopathy of liver disease: A systematic review. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, e12724.	2.3	3
12	Rate of major bleeding with ibrutinib versus bendamustine-rituximab in chronic lymphocytic leukemia: A population-based cohort study. <i>American Journal of Hematology</i> , 2022, 97, .	4.1	2
13	American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis for patients with COVID-19: March 2022 update on the use of anticoagulation in critically ill patients. <i>Blood Advances</i> , 2022, 6, 4975-4982.	5.2	21
14	Development and implementation of common data elements for venous thromboembolism research: on behalf of SSC Subcommittee on official Communication from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 297-303.	3.8	27
15	2020 ACC Expert Consensus Decision Pathway for Anticoagulant and Antiplatelet Therapy in Patients With Atrial Fibrillation or Venous Thromboembolism Undergoing Percutaneous Coronary Intervention or With Atherosclerotic Cardiovascular Disease. <i>Journal of the American College of Cardiology</i> , 2021, 77, 629-658.	2.8	144
16	Tapering thrombopoietin receptor agonists in primary immune thrombocytopenia: Expert consensus based on the RAND/UCLA modified Delphi panel method. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, 69-80.	2.3	13
17	American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19. <i>Blood Advances</i> , 2021, 5, 872-888.	5.2	310
18	Redefining outcomes in immune TTP: an international working group consensus report. <i>Blood</i> , 2021, 137, 1855-1861.	1.4	103

#	ARTICLE	IF	CITATIONS
19	Laboratory assessment of the direct oral anticoagulants: who can benefit?. <i>Kardiologia Polska</i> , 2021, 79, 622-630.	0.6	5
20	Comparative effectiveness and safety of anticoagulants for the treatment of heparin-induced thrombocytopenia. <i>American Journal of Hematology</i> , 2021, 96, 805-815.	4.1	29
21	Bleeding risk by intensity of anticoagulation in critically ill patients with COVID-19: A retrospective cohort study. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 1533-1545.	3.8	21
22	Thrombosis After Vaccination With Messenger RNA—1273: Is This Vaccine-Induced Thrombosis and Thrombocytopenia or Thrombosis With Thrombocytopenia Syndrome?. <i>Annals of Internal Medicine</i> , 2021, 174, 1468-1469.	3.9	33
23	Diagnosing heparin-induced thrombocytopenia: The need for accuracy and speed. <i>International Journal of Laboratory Hematology</i> , 2021, 43, 96-102.	1.3	10
24	Qualitative study to support the content validity of the immune thrombocytopenia (ITP) Life Quality Index (ILQI). <i>British Journal of Haematology</i> , 2021, 194, 759-766.	2.5	8
25	Definition of a critical bleed in patients with immune thrombocytopenia: Communication from the ISTH SSC Subcommittee on Platelet Immunology. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2082-2088.	3.8	14
26	Effectiveness and Safety of Direct Oral Anticoagulants Versus Warfarin in Patients With Valvular Atrial Fibrillation. <i>Annals of Internal Medicine</i> , 2021, 174, 910-919.	3.9	25
27	Self-reported positive impact of mentored clinical research training is associated with academic success in hematology. <i>Blood Advances</i> , 2021, 5, 2919-2924.	5.2	0
28	Carfilzomib-Induced Atypical Hemolytic Uremic Syndrome in a Patient With Heterozygous CFHR3/CFHR1 Deletion Treated With Eculizumab. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, e845-e849.	0.4	5
29	Immune thrombocytopenia: vaccination does not equal causation. <i>Haematologica</i> , 2021, , .	3.5	0
30	Corticosteroid overuse in adults with immune thrombocytopenia: Cause for concern. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, e12592.	2.3	15
31	Certainty of evidence and intervention's benefits and harms are key determinants of guidelines™ recommendations. <i>Journal of Clinical Epidemiology</i> , 2021, 136, 1-9.	5.0	14
32	American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: May 2021 update on the use of intermediate-intensity anticoagulation in critically ill patients. <i>Blood Advances</i> , 2021, 5, 3951-3959.	5.2	49
33	How to write a guideline: a proposal for a manuscript template that supports the creation of trustworthy guidelines. <i>Blood Advances</i> , 2021, 5, 4721-4726.	5.2	10
34	Eltrombopag treatment of patients with secondary immune thrombocytopenia: retrospective EHR analysis. <i>Annals of Hematology</i> , 2021, , 1.	1.8	2
35	Development and application of health outcome descriptors facilitated decision-making in the production of practice guidelines. <i>Journal of Clinical Epidemiology</i> , 2021, 138, 115-127.	5.0	4
36	A modeling approach to derive baseline risk estimates for GRADE recommendations: Concepts, development, and results of its application to the American Society of Hematology 2019 guidelines on prevention of venous thromboembolism in surgical hospitalized patients. <i>Journal of Clinical Epidemiology</i> , 2021, 140, 69-78.	5.0	0

#	ARTICLE	IF	CITATIONS
37	Cardiovascular and major bleeding outcomes with antiplatelet and direct oral anticoagulants in patients with acute coronary syndrome and atrial fibrillation: A population-based analysis. <i>American Heart Journal</i> , 2021, 242, 71-81.	2.7	0
38	Effectiveness and Safety of Direct Oral Anticoagulants Versus Warfarin in Patients With Valvular Atrial Fibrillation. <i>Annals of Internal Medicine</i> , 2021, 174, 1490.	3.9	3
39	Psychometric Evaluation of ITP Life Quality Index (ILQI) in a Global Survey of Patients with Immune Thrombocytopenia. <i>Advances in Therapy</i> , 2021, 38, 5791-5808.	2.9	5
40	Falsely positive heparin-induced thrombocytopenia antibody testing in severe hyperbilirubinemia. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, e12608.	2.3	0
41	Self-controlled assessment of thromboembolic event (TEE) risk following intravenous immune globulin (IGIV) in the U.S. (2006-2012). <i>Journal of Thrombosis and Thrombolysis</i> , 2021, , 1.	2.1	1
42	Creating Clinical Meaning for the Promis Cognitive Function Abilities Instrument: Improving Remission Outcomes for Adults with Thrombotic Thrombocytopenic Purpura. <i>Blood</i> , 2021, 138, 834-834.	1.4	0
43	Cost-Effectiveness of Second-Line Therapies in Adult Patients with Chronic Immune Thrombocytopenia. <i>Blood</i> , 2021, 138, 751-751.	1.4	0
44	Preferences for Accessing Patient Reported Outcomes and Health Information Among Thrombotic Thrombocytopenic Purpura Survivors. <i>Blood</i> , 2021, 138, 3039-3039.	1.4	0
45	Durability of Platelet Response When Switching from Eltrombopag or Romiplostim to Avatrombopag in Immune Thrombocytopenia (ITP): A Multicenter Study. <i>Blood</i> , 2021, 138, 1015-1015.	1.4	2
46	Sars-Cov-2 Vaccination in Patients with Pre-Existing Immune Thrombocytopenia. <i>Blood</i> , 2021, 138, 586-586.	1.4	1
47	Heparin-induced thrombocytopenia and cardiovascular surgery. <i>Hematology American Society of Hematology Education Program</i> , 2021, 2021, 536-544.	2.5	10
48	Immune thrombocytopenia in alemtuzumab-treated MS patients: Incidence, detection, and management. <i>Multiple Sclerosis Journal</i> , 2020, 26, 48-56.	3.0	36
49	Timing of Initiation of Oral Anticoagulation after Acute Ischemic Stroke in Patients with Atrial Fibrillation. <i>Pharmacotherapy</i> , 2020, 40, 55-71.	2.6	14
50	Microfluidic hemophilia models using blood from healthy donors. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020, 4, 54-63.	2.3	4
51	American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. <i>Blood Advances</i> , 2020, 4, 4693-4738.	5.2	636
52	Soluble glycoprotein VI is a predictor of major bleeding in patients with suspected heparin-induced thrombocytopenia. <i>Blood Advances</i> , 2020, 4, 4327-4332.	5.2	9
53	2020 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants. <i>Journal of the American College of Cardiology</i> , 2020, 76, 594-622.	2.8	187
54	Pharmacometric modeling to explore 4F-PCC dosing strategies for VKA reversal in patients with INR below 2. <i>Blood Advances</i> , 2020, 4, 4208-4216.	5.2	6

#	ARTICLE	IF	CITATIONS
55	Diagnostic accuracy of the <scp>PLASMIC</scp> score in patients with suspected thrombotic thrombocytopenic purpura: A systematic review and <scp>metaâ€analysis</scp>. <i>Transfusion</i> , 2020, 60, 2047-2057.	1.6	37
56	Management of heparin-induced thrombocytopenia: systematic reviews and meta-analyses. <i>Blood Advances</i> , 2020, 4, 5184-5193.	5.2	11
57	Use of direct oral anticoagulants in patients with thrombotic antiphospholipid syndrome: Guidance from the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2126-2137.	3.8	84
58	Secondâ€line treatments and outcomes for immune thrombocytopenia: A retrospective study with electronic health records. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020, 4, 1131-1140.	2.3	11
59	Maximum 24â€hour platelet count fall: Metric for improving the diagnosis of heparinâ€induced thrombocytopenia among patients with intermediate probability 4Ts scores. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2018-2024.	3.8	7
60	A user guide to the American Society of Hematology clinical practice guidelines. <i>Blood Advances</i> , 2020, 4, 2095-2110.	5.2	14
61	Development and use of clinical practice guidelines on venous thromboembolism. <i>Translational Research</i> , 2020, 225, 1-8.	5.0	0
62	Antithrombotic prophylaxis for surgery-associated venous thromboembolism risk in patients with inherited platelet disorders. The SPATA-DVT Study. <i>Haematologica</i> , 2020, 105, 1948-1956.	3.5	7
63	Methodology for the American Society of Hematology VTE guidelines: current best practice, innovations, and experiences. <i>Blood Advances</i> , 2020, 4, 2351-2365.	5.2	26
64	In-Hospital Complications and Readmission in Patients with Hemophilia Undergoing Hip or Knee Arthroplasty. <i>JBJS Open Access</i> , 2020, 5, e0085-e0085.	1.5	10
65	Diagnosing HIT: the need for speed. <i>Blood</i> , 2020, 135, 1082-1083.	1.4	5
66	Impact of gender and caregiving responsibilities on academic success in hematology. <i>Blood Advances</i> , 2020, 4, 755-761.	5.2	6
67	Second-line treatments and outcomes for immune thrombocytopenia: A retrospective study with electronic health records. , 2020, 4, 1131.		1
68	Thromboembolism and anticoagulant therapy during the COVID-19 pandemic: interim clinical guidance from the anticoagulation forum. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 50, 72-81.	2.1	362
69	Hemophilia Natural History Study (ATHN 7): Baseline Characteristics, Adverse Events, and Self-Reported Health Status of Individuals with Hemophilia a and B. <i>Blood</i> , 2020, 136, 2-3.	1.4	0
70	Tapering Thrombopoietin Receptor Agonists in Primary Immune Thrombocytopenia: Recommendations Based on the RAND/UCLA Modified Delphi Panel Method. <i>Blood</i> , 2020, 136, 6-8.	1.4	0
71	The risk of major bleeding in patients with suspected heparinâ€induced thrombocytopenia. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 1956-1965.	3.8	42
72	Treatment of Immune Thrombocytopenia in Adults: Version 2019. <i>Mayo Clinic Proceedings</i> , 2019, 94, 2161-2163.	3.0	0

#	ARTICLE	IF	CITATIONS
73	Inherited Thrombophilia and the Risk of Arterial Ischemic Stroke: A Systematic Review and Meta-Analysis. <i>Journal of the American Heart Association</i> , 2019, 8, e012877.	3.7	58
74	Thrombotic thrombocytopenic purpura: Toward targeted therapy and precision medicine. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2019, 3, 26-37.	2.3	74
75	Monoclonal immunoglobulin-associated C3 glomerulopathy and thrombotic microangiopathy: A real association?. <i>Journal of Onco-Nephrology</i> , 2019, 3, 3-10.	0.6	0
76	Favorable pharmacokinetics in hemophilia B for nonacog beta pegol versus recombinant factor IX fusion protein: A randomized trial. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2019, 3, 268-276.	2.3	12
77	Structured decision-making drives guidelines panels' recommendations "for" but not "against" health interventions. <i>Journal of Clinical Epidemiology</i> , 2019, 110, 23-33.	5.0	12
78	Reversal of direct oral anticoagulants: Guidance from the Anticoagulation Forum. <i>American Journal of Hematology</i> , 2019, 94, 697-709.	4.1	225
79	Why plasma-derived factor VIII?. <i>Haemophilia</i> , 2019, 25, e183-e185.	2.1	0
80	Different strokes for older folks (with TTP). <i>Blood</i> , 2019, 134, 2125-2126.	1.4	1
81	American Society of Hematology 2019 guidelines for immune thrombocytopenia. <i>Blood Advances</i> , 2019, 3, 3829-3866.	5.2	684
82	Extended vs. standard-duration thromboprophylaxis in acutely ill medical patients: A systematic review and meta-analysis. <i>Thrombosis Research</i> , 2019, 184, 58-61.	1.7	14
83	T2 Magnetic Resonance to Monitor Hemostasis. <i>Seminars in Thrombosis and Hemostasis</i> , 2019, 45, 247-252.	2.7	3
84	Near Universal Underestimation of the Risk of Recurrent Venous Thromboembolism (VTE)- an Institutional Survey of Thrombophilia. <i>Blood</i> , 2019, 134, 4978-4978.	1.4	0
85	Maximum 24-Hour Platelet Count Fall Rate As a Predictor of HIT. <i>Blood</i> , 2019, 134, 1072-1072.	1.4	10
86	Transitioning patients with immune thrombocytopenia to second-line therapy: Challenges and best practices. <i>American Journal of Hematology</i> , 2018, 93, 816-823.	4.1	27
87	Quality of direct oral anticoagulant prescribing in elderly patients with non-valvular atrial fibrillation: results from a large urban health system. <i>Journal of Thrombosis and Thrombolysis</i> , 2018, 46, 1-6.	2.1	7
88	The role of scientific publishing in the development of early career investigators. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2018, 2, 6-7.	2.3	2
89	Management of antithrombotic therapy in adults with immune thrombocytopenia (ITP): a survey of ITP specialists and general hematologist-oncologists. <i>Journal of Thrombosis and Thrombolysis</i> , 2018, 46, 24-30.	2.1	11
90	Statins for high cholesterol and for low platelets?. <i>Blood</i> , 2018, 131, 1159-1161.	1.4	0

#	ARTICLE	IF	CITATIONS
91	Comparative Effectiveness of Enoxaparin vsÂDalteparin for Thromboprophylaxis After Traumatic Injury. Chest, 2018, 153, 133-142.	0.8	17
92	American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia. Blood Advances, 2018, 2, 3360-3392.	5.2	448
93	Evidence to Decision framework provides a structured â€œroadmapâ€•for making GRADE guidelines recommendations. Journal of Clinical Epidemiology, 2018, 104, 103-112.	5.0	32
94	Clinical and laboratory diagnosis of TTP: an integrated approach. Hematology American Society of Hematology Education Program, 2018, 2018, 530-538.	2.5	96
95	A cross-sectional analysis of cardiovascular disease in the hemophilia population. Blood Advances, 2018, 2, 1325-1333.	5.2	43
96	The case for catheter-directed thrombolysis in selected patients with acute proximal deep vein thrombosis. Blood Advances, 2018, 2, 1799-1802.	5.2	5
97	Prospective comparison of the HEP score and 4Ts score for the diagnosis of heparin-induced thrombocytopenia. Blood Advances, 2018, 2, 3155-3162.	5.2	38
98	Evaluation of Treatment Outcomes after Second-Line Treatment Among Adult Patients with Immune Thrombocytopenia. Blood, 2018, 132, 3765-3765.	1.4	1
99	How I manage patients with anticoagulation-associated bleeding or urgent surgery. Swiss Medical Weekly, 2018, 148, w14598.	1.6	14
100	Chronic Kidney Disease (CKD) in the U.S. Hemophilia Population: A Cohort Study. Blood, 2018, 132, 2479-2479.	1.4	0
101	A Systematic Literature Review to Assess Long-Term Outcomes Associated with Splenectomy in Patients with Chronic Immune Thrombocytopenia. Blood, 2018, 132, 5881-5881.	1.4	0
102	Bleeding Related Episodes, Thrombotic Events and Platelet Counts Among Immune Thrombocytopenia Patients Receiving Second Line Therapy. Blood, 2018, 132, 2436-2436.	1.4	0
103	How Do ASH Guidelines Panels Make Decisions? Association between Decision Making Factors and the Strength of Recommendations. Blood, 2018, 132, 4707-4707.	1.4	0
104	The Influence of Activity Roles and Use of a Structured Framework on Developing Hematology Clinical Practice Guidelines. Blood, 2018, 132, 2237-2237.	1.4	0
105	Inherited Thrombophilia and the Risk of Arterial Ischemic Stroke: A Systematic Review and Meta-Analysis. Blood, 2018, 132, 2518-2518.	1.4	0
106	Profile of Instrumentation Laboratoryâ€™s HemosILÂ® AcuStar HIT-Ab(PF4-H) assay for diagnosis of heparin-induced thrombocytopenia. Expert Review of Molecular Diagnostics, 2017, 17, 419-426.	3.1	11
107	Heparin-Induced Thrombocytopenia in Cardiac Surgery Patients. Seminars in Thrombosis and Hemostasis, 2017, 43, 691-698.	2.7	48
108	Reduced-Intensity Rivaroxaban for the Prevention of Recurrent Venous Thromboembolism. New England Journal of Medicine, 2017, 376, 1279-1280.	27.0	3

#	ARTICLE	IF	CITATIONS
109	Inappropriate documentation of heparin allergy in the medical record because of misdiagnosis of heparin-induced thrombocytopenia: frequency and consequences. <i>Journal of Thrombosis and Haemostasis</i> , 2017, 15, 370-374.	3.8	15
110	2017 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants. <i>Journal of the American College of Cardiology</i> , 2017, 70, 3042-3067.	2.8	285
111	Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant. <i>New England Journal of Medicine</i> , 2017, 377, 2215-2227.	27.0	549
112	Clinical Scoring Systems in Thrombosis and Hemostasis. <i>Seminars in Thrombosis and Hemostasis</i> , 2017, 43, 447-448.	2.7	3
113	Measurement and reversal of the direct oral anticoagulants. <i>Blood Reviews</i> , 2017, 31, 77-84.	5.7	133
114	Laboratory Assessment of the Anticoagulant Activity of Direct Oral Anticoagulants. <i>Chest</i> , 2017, 151, 127-138.	0.8	245
115	Clot stability as a determinant of effective factor VIII replacement in hemophilia A. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2017, 1, 231-241.	2.3	30
116	Polyphosphate/platelet factor 4 complexes can mediate heparin-independent platelet activation in heparin-induced thrombocytopenia. <i>Blood Advances</i> , 2016, 1, 62-74.	5.2	58
117	Prospective, multicenter study of postoperative deep-vein thrombosis in patients with haemophilia undergoing major orthopaedic surgery. <i>Thrombosis and Haemostasis</i> , 2016, 116, 42-49.	3.4	28
118	Diagnostic accuracy of rapid immunoassays for heparin-induced thrombocytopenia. <i>Thrombosis and Haemostasis</i> , 2016, 115, 1044-1055.	3.4	56
119	Management of the multiple phases of heparin-induced thrombocytopenia. <i>Thrombosis and Haemostasis</i> , 2016, 116, 835-842.	3.4	43
120	Management of Periprocedural Anticoagulation. <i>Journal of the American College of Cardiology</i> , 2016, 68, 217-226.	2.8	45
121	Rapid Evaluation of Platelet Function With T2 Magnetic Resonance. <i>American Journal of Clinical Pathology</i> , 2016, 146, 681-693.	0.7	9
122	Commentary on: Rivaroxaban for Venous Thromboembolism Prophylaxis in Abdominoplasty: A Multicenter Experience. <i>Aesthetic Surgery Journal</i> , 2016, 36, 67-70.	1.6	6
123	Does my patient have HIT? There should be an app for that. <i>Blood</i> , 2016, 127, 522-524.	1.4	6
124	Adjuvant rituximab to prevent TTP relapse. <i>Blood</i> , 2016, 127, 2952-2953.	1.4	18
125	How I treat refractory immune thrombocytopenia. <i>Blood</i> , 2016, 128, 1547-1554.	1.4	114
126	Controversies in the treatment of immune thrombocytopenia. <i>Current Opinion in Hematology</i> , 2016, 23, 479-485.	2.5	33

#	ARTICLE	IF	CITATIONS
127	Guidance for the practical management of the heparin anticoagulants in the treatment of venous thromboembolism. <i>Journal of Thrombosis and Thrombolysis</i> , 2016, 41, 165-186.	2.1	156
128	Laboratory measurement of the non-vitamin K antagonist oral anticoagulants: selecting the optimal assay based on drug, assay availability, and clinical indication. <i>Journal of Thrombosis and Thrombolysis</i> , 2016, 41, 241-247.	2.1	61
129	Spk-9001: Adeno-Associated Virus Mediated Gene Transfer for Hemophilia B Achieves Sustained Mean Factor IX Activity Levels of >30% without Immunosuppression. <i>Blood</i> , 2016, 128, 3-3.	1.4	24
130	Heparin-Induced Thrombocytopenia: Diagnosis and Management. , 2016, , 519-529.		0
131	Hemophilia a Clots Generated with Recombinant Factor VIIa Differed in Structure and Composition from Those Formed with Factor VIII. <i>Blood</i> , 2016, 128, 3798-3798.	1.4	0
132	Characterization of Bleeding in Hemophilia Carriers and Comparison to Women with Type 1 Von Willebrand Disease, Type 3 Von Willebrand Disease Obligate Carriers and Controls. <i>Blood</i> , 2016, 128, 875-875.	1.4	0
133	Monitoring and reversal of direct oral anticoagulants. <i>Hematology American Society of Hematology Education Program</i> , 2015, 2015, 117-124.	2.5	50
134	ITP and TTP: interpreting evidence in light of patient values. <i>Blood</i> , 2015, 125, 1514-1515.	1.4	5
135	Microsurgery and the Hypercoagulable State. <i>Plastic and Reconstructive Surgery</i> , 2015, 136, 545e-552e.	1.4	38
136	Laboratory measurement of the anticoagulant activity of edoxaban: a systematic review. <i>Journal of Thrombosis and Thrombolysis</i> , 2015, 39, 288-294.	2.1	92
137	Can Immune Thrombocytopenia Be Cured with Medical Therapy?. <i>Seminars in Thrombosis and Hemostasis</i> , 2015, 41, 395-404.	2.7	63
138	Analysis of 65 pregnancies in 34 women with five different forms of inherited platelet function disorders. <i>British Journal of Haematology</i> , 2015, 170, 559-563.	2.5	35
139	Practical Management of Anticoagulation in Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2015, 65, 1340-1360.	2.8	92
140	Monitoring and reversal of direct oral anticoagulants. <i>Hematology American Society of Hematology Education Program</i> , 2015, 2015, 117-124.	2.5	12
141	A Cross-Sectional Analysis of Cardiovascular Disease in the Hemophilia Population. <i>Blood</i> , 2015, 126, 761-761.	1.4	2
142	Inappropriate Listing of Heparin As an Allergy in the Electronic Medical Record Due to Misdiagnosis of Heparin-Induced Thrombocytopenia: Frequency and Consequences. <i>Blood</i> , 2015, 126, 3479-3479.	1.4	0
143	Atherosclerosis is not a risk factor for antiplatelet factor 4/heparin antibody formation after cardiopulmonary bypass surgery. <i>Thrombosis and Haemostasis</i> , 2014, 111, 1191-1193.	3.4	1
144	Clinical and Laboratory Diagnosis of Heparin-Induced Thrombocytopenia: An Integrated Approach. <i>Seminars in Thrombosis and Hemostasis</i> , 2014, 40, 106-114.	2.7	102

#	ARTICLE	IF	CITATIONS
145	T2 Magnetic Resonance: A Diagnostic Platform for Studying Integrated Hemostasis in Whole Blood—Proof of Concept. <i>Clinical Chemistry</i> , 2014, 60, 1174-1182.	3.2	26
146	DiagnostiC assays for heparin-induced thrombocytopenia. <i>British Journal of Haematology</i> , 2014, 166, 631-633.	2.5	2
147	Hospital-Acquired Thrombocytopenia. <i>Hospital Practice (1995)</i> , 2014, 42, 142-152.	1.0	8
148	Autoantibodies in Heparin-Induced Thrombocytopenia. , 2014, , 511-518.		0
149	Laboratory Measurement of the Anticoagulant Activity of the Non- Vitamin Oral Anticoagulants. <i>Journal of the American College of Cardiology</i> , 2014, 64, 1128-1139.	2.8	414
150	The 4Ts test in the critically ill: Timing is everything. <i>Journal of Critical Care</i> , 2014, 29, 468-469.	2.2	6
151	Pathogenesis of immune thrombocytopenia. <i>Presse Medicale</i> , 2014, 43, e49-e59.	1.9	101
152	Reversal of target-specific oral anticoagulants. <i>Drug Discovery Today</i> , 2014, 19, 1465-1470.	6.4	32
153	A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia. <i>Blood</i> , 2014, 123, 3887-3894.	1.4	112
154	Analysis of 339 pregnancies in 181 women with 13 different forms of inherited thrombocytopenia. <i>Haematologica</i> , 2014, 99, 1387-1394.	3.5	63
155	Thrombocytopenia in the Intensive Care Unit and After Solid Organ Transplantation. , 2014, , 115-132.		1
156	Investigation of a potential protective mechanism against heparin-induced thrombocytopenia in patients on chronic intermittent hemodialysis. <i>Thrombosis Research</i> , 2013, 131, 244-248.	1.7	2
157	Reversal of novel oral anticoagulants in patients with major bleeding. <i>Journal of Thrombosis and Thrombolysis</i> , 2013, 35, 391-398.	2.1	78
158	Novel diagnostic assays for heparin-induced thrombocytopenia. <i>Blood</i> , 2013, 121, 3727-3732.	1.4	41
159	Protamine-induced thrombocytopenia?. <i>Blood</i> , 2013, 121, 2818-2819.	1.4	8
160	Current and Emerging Therapeutics for Heparin-Induced Thrombocytopenia. <i>Seminars in Thrombosis and Hemostasis</i> , 2012, 38, 31-37.	2.7	18
161	Unfractionated Heparin for the Treatment of Venous Thromboembolism: Best Practices and Areas of Uncertainty. <i>Seminars in Thrombosis and Hemostasis</i> , 2012, 38, 593-599.	2.7	37
162	Free Tissue Transfer in the Hypercoagulable Patient. <i>Plastic and Reconstructive Surgery</i> , 2012, 129, 443-453.	1.4	136

#	ARTICLE	IF	CITATIONS
163	How I treat heparin-induced thrombocytopenia. <i>Blood</i> , 2012, 119, 2209-2218.	1.4	135
164	VWF sequence variants: innocent until proven guilty. <i>Blood</i> , 2012, 119, 1959-1960.	1.4	1
165	Dynamic antibody-binding properties in the pathogenesis of HIT. <i>Blood</i> , 2012, 120, 1137-1142.	1.4	65
166	Predictive value of the 4Ts scoring system for heparin-induced thrombocytopenia: a systematic review and meta-analysis. <i>Blood</i> , 2012, 120, 4160-4167.	1.4	393
167	Overuse of Computed Tomography Pulmonary Angiography in the Evaluation of Patients with Suspected Pulmonary Embolism in the Emergency Department. <i>Academic Emergency Medicine</i> , 2012, 19, 1219-1226.	1.8	75
168	Nitrated fibrinogen is a biomarker of oxidative stress in venous thromboembolism. <i>Free Radical Biology and Medicine</i> , 2012, 53, 230-236.	2.9	31
169	Miniaturized T2MR Magnetic Resonance System for Analysis of Hemostasis and Detection of Impaired and Prothrombotic Blood Disorders. <i>Blood</i> , 2012, 120, 1118-1118.	1.4	6
170	Novel Diagnostic Assays for Heparin-Induced Thrombocytopenia. <i>Blood</i> , 2012, 120, 267-267.	1.4	1
171	Update in the diagnosis and management of heparin-induced thrombocytopenia. <i>Clinical Advances in Hematology and Oncology</i> , 2012, 10, 453-5.	0.3	2
172	Heparin-induced thrombocytopenia (HIT) in 2011: An epidemic of overdiagnosis. <i>Thrombosis and Haemostasis</i> , 2011, 106, 993-994.	3.4	81
173	False normal von Willebrand factor activity by monoclonal antibody-based ELISA in a patient with type 2A(IIID) von Willebrand disease. <i>Thrombosis and Haemostasis</i> , 2011, 106, 1224-1225.	3.4	4
174	Recent advances in heparin-induced thrombocytopenia. <i>Current Opinion in Hematology</i> , 2011, 18, 315-322.	2.5	20
175	A distinctive form of immune thrombocytopenia in a phase 2 study of alemtuzumab for the treatment of relapsing-remitting multiple sclerosis. <i>Blood</i> , 2011, 118, 6299-6305.	1.4	96
176	Heparin-induced thrombocytopenia: present and future. <i>Journal of Thrombosis and Thrombolysis</i> , 2011, 31, 353-366.	2.1	39
177	The HIT Expert Probability (HEP) Score: a novel pretest probability model for heparin-induced thrombocytopenia based on broad expert opinion. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 2642-2650.	3.8	229
178	Interlaboratory variation in heparin monitoring: Lessons from the Quality Management Program of Ontario coagulation surveys. <i>Thrombosis and Haemostasis</i> , 2010, 104, 837-844.	3.4	30
179	Immune Thrombocytopenia. <i>Hematology American Society of Hematology Education Program</i> , 2010, 2010, 377-384.	2.5	63
180	Evidence-Based Mini-Review: Is Indium-Labeled Autologous Platelet Scanning Predictive of Response to Splenectomy in Patients With Chronic Immune Thrombocytopenia?. <i>Hematology American Society of Hematology Education Program</i> , 2010, 2010, 385-386.	2.5	37

#	ARTICLE	IF	CITATIONS
181	Safety of the Thrombopoiesis-Stimulating Agents for the Treatment of Immune Thrombocytopenia. <i>Current Drug Safety</i> , 2010, 5, 171-181.	0.6	25
182	Toxicities of the Thrombopoietic Growth Factors. <i>Seminars in Hematology</i> , 2010, 47, 289-298.	3.4	49
183	Immune Thrombocytopenia. <i>Hematology American Society of Hematology Education Program</i> , 2010, 2010, 377-384.	2.5	11
184	ASH evidence-based guidelines: is the IgG-specific anti-PF4/heparin ELISA superior to the polyspecific ELISA in the laboratory diagnosis of HIT?. <i>Hematology American Society of Hematology Education Program</i> , 2009, 2009, 250-252.	2.5	28
185	Interlaboratory agreement in the monitoring of unfractionated heparin using the anti-factor Xa-correlated activated partial thromboplastin time. <i>Journal of Thrombosis and Haemostasis</i> , 2009, 7, 80-86.	3.8	58
186	A Bloody Mystery. <i>New England Journal of Medicine</i> , 2009, 361, 1887-1894.	27.0	13
187	Romiplostim: chronic therapy for a chronic disease?. <i>Blood</i> , 2009, 113, 2122-2123.	1.4	1
188	Interlaboratory Precision in the Monitoring of Unfractionated Heparin Using the Anti-Factor Xa-Correlated Activated Partial Thromboplastin Time. <i>Blood</i> , 2008, 112, 435-435.	1.4	10
189	Initial Safety, Pharmacokinetic and Pharmacodynamic Data from a Phase I Clinical Trial of Systemic C-MYB Antisense Oligodeoxynucleotide in Subjects with Refractory Hematologic Malignancies. <i>Blood</i> , 2008, 112, 4033-4033.	1.4	0
190	Similarity in Joint Function Limitation in Type 3 VWD and Moderate Hemophilia A. <i>Blood</i> , 2008, 112, 426-426.	1.4	5
191	Bleeding Symptoms and Laboratory Correlation in 150 Patients with Severe von Willebrand Disease.. <i>Blood</i> , 2007, 110, 2134-2134.	1.4	0
192	MPLW515L Is a Novel Somatic Activating Mutation in Myelofibrosis with Myeloid Metaplasia. <i>PLoS Medicine</i> , 2006, 3, e270.	8.4	1,222
193	Epigenetic abnormalities associated with a chromosome 18(q21-q22) inversion and a Gilles de la Tourette syndrome phenotype. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 4684-4689.	7.1	73